Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/2090| Title: | A cautionary tale of the use of lenalidomide and dexamethasone for relapsed/refractory immunoglobulin light chain (AL) amyloidosis. |
| Epworth Authors: | Prince, Miles |
| Keywords: | Lenalidomide Dexamethasone Immunoglobulin Light Chain (AL) Amyloidosis Relapsed/Refractory Predictors of Efficacy Toxicities RD Combination Department of Haematology, Epworth HealthCare, Melbourne, Victoria, Australia Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia |
| Issue Date: | Oct-2021 |
| Publisher: | Wiley Blackwell |
| Citation: | Br J Haematol . 2021 Oct;195(2):160-161 |
| Abstract: | Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. Basset M, Kimmich CR, Schreck N, Krzykalla J, Dittrich T, Veelken K, Goldschmidt H, Seckinger A, Hose D, Jauch A, Müller-Tidow C, Benner A, Hegenbart U, Schönland SO. Br J Haematol. 2021 Oct;195(2):230-243. doi: 10.1111/bjh.17685. Epub 2021 Aug 3. PMID: 34341985 |
| URI: | http://hdl.handle.net/11434/2090 |
| DOI: | 10.1111/bjh.17710 |
| URL: | https://pubmed.ncbi.nlm.nih.gov/34374083/ |
| ISSN: | 0007-1048 1365-2141 |
| Journal Title: | British Journal of Haematology |
| Type: | Comments |
| Affiliated Organisations: | Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. |
| Appears in Collections: | Cancer Services |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.